Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY

Dr. Jitendra Singh conferred Lifetime Achievement Award

Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials

Fostering closer ties between industry & academia imperative for sustainable growth

The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT